Patient With Multiple Brain Metastases
A 59-year-old with a primary asymptomatic bronchogenic adenocarcinoma and multiple brain metastases. The patient was treated with cyclic chemotherapy consisting of: docetaxel (Taxotere), carboplatin, and bevacizumab (Avastin). What portion of the patient’s therapy is most likely responsible for the acne-like eruption? (Source: Cancer Network)
Source: Cancer Network - July 1, 2013 Category: Cancer & Oncology Source Type: news
Xtandi™ (Enzalutamide) Authorised In The European Union (EU) For Advanced Prostate Cancer
Enzalutamide authorised in European Union (EU) for the treatment of adult men with metastatic castrationresistant prostate cancer whose disease has progressed on or after docetaxel therapy[1] Astellas Pharma Europe Ltd., the European Headquarters of Tokyobased Astellas Pharma Inc. (TSE:4503), and Medivation, Inc... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 26, 2013 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news
Xeloda for Metastatic Breast Cancer
Xeloda or capecitabine is an oral chemotherapy drug that you take twice a day with water and on a full stomach. It is used to treat metastatic breast cancer, and can be taken alone or with Taxotere. Read more to learn about how Xeloda works, its side effects, and self-care tips. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - June 10, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
ASCO: Adding Curcuminoids to Docetaxel Shows Promise in Castration-Resistant Prostate Cancer
Addition of curcuminoids to treatment with docetaxel was well tolerated and showed promise in improving the response rate to docetaxel “in terms of both PSA decrease and objective response” in a phase II trial in patients with castration-resistant prostate cancer. (Source: Cancer Network)
Source: Cancer Network - June 5, 2013 Category: Cancer & Oncology Source Type: news
Nintedanib* plus chemotherapy
The LUME-Lung 1 Phase III clinical trial results showed that the novel investigational compound nintedanib*, an oral triple angiokinase inhibitor, extended life by 2.3 months for non-small cell lung cancer (NSCLC) adenocarcinoma patients when added to docetaxel, versus placebo plus docetaxel. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 4, 2013 Category: Drugs & Pharmacology Source Type: news
Novel Agent Shows Potential for Advanced Lung CancerNovel Agent Shows Potential for Advanced Lung Cancer
A novel heat shock protein inhibitor that acts as a molecular 'chaperone' showed promising activity when added to docetaxel in advanced lung cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 3, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Docetaxel-Cisplatin and Docetaxel-Capecitabine in TNBCDocetaxel-Cisplatin and Docetaxel-Capecitabine in TNBC
Should platinum be the gold-standard in triple-negative breast cancer treatment regimens? Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 3, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Tearing Related to Docetaxel-Based ChemotherapyTearing Related to Docetaxel-Based Chemotherapy
Tearing occurs in the majority of patients who receive adjuvant docetaxel-based chemotherapy regimens, but it is not caused by lacrimal duct obstruction. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 10, 2013 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
OncoGenex Announces That The Borealis-2(TM) Clinical Trial Of OGX-427 In Previously Treated Metastatic Bladder Cancer Is Now Open For Enrollment
The OGX-427 ORCA™ Program Continues to Expand with Patient Enrollment Now Open for Second Phase 2 Trial of OGX-427 in Advanced Bladder Cancer OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) have announced initiation of the Borealis-2™ clinical trial, an investigator-sponsored, randomized Phase 2 trial evaluating OGX-427 in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy treatment... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 2, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news
Positive CHMP Opinion For Xtandi™ (Enzalutamide) In Advanced Prostate Cancer
Enzalutamide recommended for approval in the European Union (EU) for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy 1 Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 30, 2013 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news
Zibotentan No Extra Help in Refractory Prostate CancerZibotentan No Extra Help in Refractory Prostate Cancer
Adding zibotentan to docetaxel for refractory prostate cancer doesn't improve survival, researchers say. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 19, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Gefitinib plus docetaxel failed to improve OS in SCCHN
Argiris AE. J Clin Oncol. 2013;doi:10.1200/JCO.2012.45.4272. (Source: HemOncToday.com)
Source: HemOncToday.com - April 19, 2013 Category: Cancer & Oncology Source Type: news
Zibotentan/docetaxel failed to improve OS in metastatic castration-resistant prostate cancer
(Source: HemOncToday.com)
Source: HemOncToday.com - April 17, 2013 Category: Cancer & Oncology Source Type: news
Carboplatin-Paclitaxel vs Other Platinum-Doublets in Advanced NSCLCCarboplatin-Paclitaxel vs Other Platinum-Doublets in Advanced NSCLC
In elderly patients with advanced non-small cell lung cancer and squamous cell histology, carboplatin plus paclitaxel yields slightly better survival than carboplatin with either gemcitabine or docetaxel. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 16, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Positive Clinical Data Presented For Lead Accurin Candidate BIND-014 In Cancer Patients
BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, has announced that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented in an oral presentation at the American Association for Cancer Research (AACR) 2013 Annual Meeting. Clinical investigators presented the Phase 1 results with BIND-014, its targeted docetaxel Accurin, in 28 heavily-pretreated patients with advanced or metastatic solid tumors... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 12, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
